Etonogestrel (e.g. Nexplanon®) implant for contraception

Provenance

Written by SPS and the College of Sexual and Reproductive Healthcare (CoSRH), with the support of specialist stakeholders working within clinical practice, for use within reproductive services.

August 2025 – note the Faculty of Sexual and Reproductive Healthcare (FSRH) has now changed its name to the College of Sexual and Reproductive Healthcare (CoSRH). Some web pages and CoSRH documents will continue to display the FSRH name; where you see FSRH, this refers to CoSRH. All weblinks are still active.

Templates available

Version 3.0 of this PGD template, valid from September 2026, has been published to allow organisations to undertake local governance processes in a timely manner.

Version 2.1 of this PGD template remains currently valid and will be removed from this page on its expiry (31st August 2026).

Planned update

Change to licence: extension of use to 5 years issued May 2026

The MHRA have updated the Summary of Product Characteristics (SPC) for the etonogestrel implant (Nexplanon®) and it is now licensed for use for up to 5 years in the UK.

We are in the process of updating version 3.0 of the etonogestrel implant (Nexplanon®) PGD template (published April 2026, before the licence change) to the 5 year duration of use, with the support of the CoSRH. This updated PGD template is expected to be published in July 2026.

In the interim, services who have not authorised version 3.0 of the PGD template may wish to amend the template with the updated duration of use, with the agreement of their local development group.

For further information see CoSRH CEU statement: extension of use of the etonogestrel implant (Nexplanon®) to 5 years

PGD template attachment

The template PGD is attached below to download and use in conjunction with our implementation advice (SPS page).

• Etonorgestrel Implant National PGD template V2.1 accessible 11.24Opens in a new window · Word · 75 KB
• Etonogestrel Implant National PGD template V3.0 accessible 04.26Opens in a new window · Word · 76 KB

More reproductive health PGD templates

• Medroxyprogesterone acetate (SC-DMPA) injection for contraception
• Lidocaine injection for subdermal etonogestrel in contraception
• Ulipristal acetate 30mg tablets for emergency contraception
• Progestogen only pill (POP) for contraception
• Lidocaine plus prilocaine cream for IUD insertion or removal
• Levonorgestrel 1500 microgram tablets for emergency contraception
• Progestogen-Only Intra-Uterine Device (LNG-IUD) for contraception
• Lidocaine 10mg/ml spray for IUD insertion or removal
• Copper Intrauterine Device (Cu-IUD)
• Combined hormonal contraceptive transdermal patch
• Combined hormonal contraceptive vaginal ring
• Combined oral hormonal contraceptive (COC) in reproductive health
• Medroxyprogesterone acetate (DMPA) IM injection for contraception

All PGD templates

Update history